Ajanta Pharma
2,628.50
+21.80(+0.84%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D+0.84%
1M+0.68%
6M+1.63%
1Y-12.09%
5Y+147.15%
View Company Insightsright
More news about Ajanta Pharma
10Sept 25
Ajanta Pharma Promoter Releases Pledge on 130,000 Shares for Refinancing
Ravi Agrawal, a key promoter of Ajanta Pharma Limited, has released a pledge on 130,000 shares for refinancing purposes. The company has filed the necessary regulatory disclosures with both BSE and NSE in compliance with SEBI regulations. This action may be viewed positively by the market as it could indicate the promoter's confidence in the company's financial stability.
19Aug 25
IT Department Raids Ajanta Pharma Premises
The Income Tax Department has conducted raids at Ajanta Pharma's premises. While the raid has been confirmed, specific details about its scope, duration, or reasons remain undisclosed. This development has raised concerns in the pharmaceutical sector, potentially affecting Ajanta Pharma's operations, reputation, and market standing. Stakeholders are awaiting further information about the nature of the investigation and its possible impact on the company's business operations.
28Jul 25
Ajanta Pharma Reports Robust Q1 Results with 14% Revenue Growth
Ajanta Pharma announced robust Q1 financial results, with consolidated revenue increasing 14% to ₹1,303.00 crore. Net profit rose 4% to ₹255.00 crore, while EBITDA grew 6% to ₹351.00 crore. The branded generics segment, accounting for 73% of total revenue, grew by 9% to ₹941.00 crore. US generics showed exceptional growth of 36%, reaching ₹310.00 crore. The company launched 8 new products in India and 12 in emerging markets during the quarter.
14Jul 25
Ajanta Pharma: Significant Block Trade of 3.16 Lakh Shares on NSE
A significant block trade of approximately 3.16 lakh (315,631) shares of Ajanta Pharma was executed on the National Stock Exchange (NSE). The transaction occurred at Rs. 2,619.50 per share, totaling Rs. 82.68 crore. This large-scale trade indicates substantial market interest in the pharmaceutical company's stock, potentially impacting its short-term price and trading volumes.
02May 25
Ajanta Pharma Q4 FY25: Revenue Grows, Margins Shrink Amid Market Challenges
Ajanta Pharma's Q4 FY25 results show 11% YoY revenue growth to Rs 11.70 billion and 11.10% PAT increase to Rs 2.30 billion. EBITDA grew 6.80% YoY to Rs 2.97 billion, but margins contracted. Systematix maintains 'Buy' rating with revised target price. Results published in Business Standard and Navakal on May 1, 2025.
30Apr 25
Ajanta Pharma Reports 11% Growth in Q4 Profit and Revenue, Margin Contracts
Ajanta Pharma Limited announced strong Q4 FY2025 results with revenue up 11% to ₹1,170.00 crore and net profit increasing 12.50% to ₹225.00 crore. EBITDA grew 6.83% to ₹297.00 crore, though the EBITDA margin slightly decreased. The company distributed ₹700.00 crore to shareholders in FY2025, representing 76% of PAT. An earnings conference call is scheduled for April 30, 2025, to discuss the results further.
21Mar 25
Ajanta Pharma Joins FTSE All World Index, Expands Manufacturing Capacity
Ajanta Pharma has been added to the FTSE All World Index, potentially attracting $23.80 million in foreign investment. The company also announced plans to triple its liquid formulation production capacity from 6 million to 18 million bottles annually at its Pithampur site. This Rs. 92 crore expansion project, funded through internal accruals, is expected to be completed by Q1 FY 2026.
20Mar 25
Ajanta Pharma to Invest ₹92 Crore in Pithampur Facility Expansion
Ajanta Pharma Limited plans to invest ₹92 crore to expand its Pithampur manufacturing site, adding a new liquid formulation facility. The expansion will increase production capacity from 6 million to 18 million bottles per annum on a single shift basis. The project, financed through internal accruals, is set to be completed by Q1 FY 2026. This strategic move aims to meet growing global demand and alleviate current production pressures, with the existing facility operating at 175% utilization.
Ajanta Pharma
2,628.50
+21.80
(+0.84%)
1 Year Returns:-12.09%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)